URGN: ZUSDURI's rapid adoption and pipeline innovation position the company for sustained growth
The event highlighted strong momentum for ZUSDURI, driven by first-mover advantage, expanding prescriber base, and robust payer coverage. Next-generation products and pipeline expansion, including UGN-103, UGN-104, and UGN-501, support long-term growth and diversification.Based on UroGen Pharma Ltd…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.